SCHEDULE 13G/A: BlackRock Amends Chemours Stake, Reports 16.9% Beneficial Ownership

BlackRock, Inc. has filed an amendment to its Schedule 13G, disclosing a 16.9% beneficial ownership stake in Chemours Company common stock as of June 30, 2025.

Summary

• BlackRock, Inc. reported beneficial ownership of 25,235,416 shares of Chemours Company common stock.
• This ownership represents 16.9% of the total outstanding common stock of Chemours Company.
• BlackRock, Inc. holds sole voting power over 24,977,712 shares.
• BlackRock, Inc. holds sole dispositive power over 25,235,416 shares.
• No shared voting or dispositive power was reported.
• The filing is an Amendment No. 14 to Schedule 13G.
• iShares Core S&P Small-Cap ETF, a BlackRock entity, is identified as having an interest of more than 5% in Chemours Company common stock.
• BlackRock Fund Advisors is also noted as an entity beneficially owning 5% or greater of the outstanding shares.

Sentiment

Score: 5

Explanation: The document is a factual report of beneficial ownership, providing neutral information without explicit positive or negative sentiment regarding the company's performance or outlook.

Positives

• BlackRock, Inc., a major institutional investor, maintains a significant 16.9% beneficial ownership stake in Chemours Company, indicating continued investment interest.

Risks

• The 'Date of Event Which Requires Filing of this Statement' is listed as June 30, 2025, which is a future date, potentially indicating a forward-looking reporting period or a clerical anomaly in the filing.

Future Outlook

NA

Industry Context

This Schedule 13G filing indicates a significant passive ownership stake by BlackRock, Inc., one of the world's largest asset managers, in Chemours Company. Such filings are standard disclosures for institutional investors holding more than 5% of a company's stock, signaling their investment positions without intent to control or influence management. The amendment suggests an ongoing adjustment or re-affirmation of BlackRock's position in Chemours.

Stakeholder Impact

• Shareholders: The continued significant stake by BlackRock may be viewed positively as a vote of confidence from a major institutional investor.

Key Dates

Keywords

BlackRock, Chemours Company, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Equity Stake, Asset Management